Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 15 May 1998:
Vol. 280. no. 5366, p. 997
DOI: 10.1126/science.280.5366.997
Prev | Table of Contents | Next

News & Comment

CANCER:
The Roadblocks to Angiogenesis Blockers

Eliot Marshall

Although compounds that block the development of new blood vessels have shown great promise in treating cancer in mice, human clinical trials are still at least 2 years away, according to researchers, in part because it is not yet possible to produce the necessary quantities of the compounds. So experts on cancer drugs were surprised by the heated speculation last week over two of these so-called antiangiogenesis compounds, angiostatin and endostatin.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Improved Therapeutic Effectiveness by Combining Recombinant CXC Chemokine Ligand 10 with Cisplatin in Solid Tumors.
G. Li, L. Tian, J.-m. Hou, Z.-y. Ding, Q.-m. He, P. Feng, Y.-j. Wen, F. Xiao, B. Yao, R. Zhang, et al. (2005)
Clin. Cancer Res. 11, 4217-4224
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)